News

Media Release

Hyphens Pharma wins Gold Award for Best Managed Board at Singapore Corporate Awards 2024

Download as PDF

Singapore, 28 August 2024 – Hyphens Pharma International Limited (“Hyphens Pharma”, “凯帆药剂国际有限公司”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that the Company has been conferred the Gold Award for Best Managed Board under the category of listed companies with market capitalisation of less than S$300 million at the prestigious Singapore Corporate Awards 2024.

Mr Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, received the award from the Guest of Honour, Mr Heng Swee Keat, Deputy Prime Minister, at the awards ceremony held on 27 August 2024. 

The Singapore Corporate Awards (“SCA”) represents Singapore’s highest accolade in corporate governance and is jointly organised by the Institute of Singapore Chartered Accountants (“ISCA”), the Singapore Institute of Directors (“SID”) and The Business Times, supported by the Accounting and the Corporate Regulatory Authority (“ACRA”) and Singapore Exchange (“SGX”).

Mr Lim See Wah, Executive Chairman and CEO of Hyphens Pharma said: “We are delighted and honoured to receive this prestigious accolade which is a testament to the collective effort, dedication and exceptional leadership demonstrated by our Board and supported by our management team. This achievement is a reflection of our Board’s strategic vision and commitment to corporate governance. I wish to acknowledge the tireless efforts of our Board, as well as the management team, employees, and partners whose hard work and dedication have made such an achievement possible.”

The Best Managed Board award entailed a rigorous three-stage screening process. All listed companies were screened based on publicly available information on total shareholder returns, corporate governance practices, and corporate governance indices.

Companies are selected based on the assessment of the following criteria:

• Overall quality of corporate governance as reflected in board and committee structure, practices, and external validation;
• Board composition and accountability: independence, skill-mix, board and gender diversity, working relationships, commitment, etc.;
• Board functions: principles and processes, meeting and information management, committee functioning, board evaluation;
• Performance orientation: board, director and executive performance management, strategic guidance and company performance monitoring, performance-linked executive compensation;
• Managing company leadership: access to management, balance of power, succession planning and talent development;
• Directors’ development and recognition: board orientation, on-going development, alignment of compensation with shareholders’ interests;
• Corporate transparency and governance disclosure: financial disclosure content and context, governance compliance, and reasons for non-compliance;
• Shareholders’ Interest: shareholder value creation and return to shareholders, shareholder communications and meetings;
• Risk management: risk management framework and processes;
• Corporate social responsibility and sustainability: policies and practices.

Additional inputs on shortlisted companies were obtained through research and discreet inquiries. The shortlisted boards were then interviewed and ranked by a panel of judges. The objective of the Best Managed Board award is to reward boards’ commitment to transparency, accountability, performance orientation, good processes and practices, provide a multi-dimensional view of board effectiveness, underscore the importance of human capital practices at the board level and increase benchmarks by bringing the best out of board practices in Singapore.

 

End.

 

About Hyphens Pharma International Limited                 (www.hyphensgroup.com)

Hyphens Pharma International Limited and its subsidiaries (the “Group”) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries.

The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 14 other markets – Bangladesh, Brunei, Cambodia, Hong Kong S.A.R., Macau S.A.R., Myanmar, South Korea, Sri Lanka and Gulf Cooperation Council countries, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates.

Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients’ homes.

Issued on behalf of : Hyphens Pharma International Limited
For media enquires contact : Mr Derek Chng / Mr Gerald Woon
Email / DID / Mobile : [email protected] / (65) 6704 9285 / (65) 9638 8635
[email protected] / (65) 6704 9268 / (65) 9694 8364

This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21- 00 AIA Tower, Singapore 048542.